VYD 224
Alternative Names: VYD-224Latest Information Update: 14 Jul 2023
At a glance
- Originator Invivyd
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 14 Jul 2023 VYD 224 is available for licensing in Europe, World as of 14 Jul 2023. https://invivyd.com/partners/
- 13 Jul 2023 Preclinical trials in COVID-2019 infections (Prevention) in USA (Parenteral) (Invivyd pipeline, July 2023)
- 13 Jul 2023 Preclinical trials in COVID-2019 infections in USA (Parenteral) (Invivyd pipeline, July 2023)